Background: Vitamin C is known to both inhibit melanin formation and reduce oxidized melanin. However, vitamin C does not easily penetrate the skin. In this study, vitamin C iontophoresis was employed in order to enhance vitamin C penetration. Objective: The purpose of this study was to evaluate the efficacy of vitamin C iontophoresis for melasma patients. Methods: Twenty-nine females with melasma were enrolled. For iontophoresis, a vitamin C solution was applied to one side of the face, while distilled water was applied to the other side as a control. The L (luminance) value was measured by a colorimeter to obtain an objective pigmentation parameter. Results: Twelve weeks after iontophoresis, the colorimeter of the treated site showed a significant decrease in the L value (from 4.60 to 2.78, p = 0.002), compared to that of the control site (from 4.45 to 3.87, p = 0.142). Conclusion: Vitamin C iontophoresis may be an effective treatment modality for melasma.

Keywords:
Vitamin C, Ascorbic acid, Iontophoresis, Melasma, Chloasma, Magnesium-L- ascorbyl-2-phosphate
1.
Lerner AB, Fitzpatrick TB: Biochemistry of melanin formation. Physiol Rev 1950;30:91–126.
2.
Ros JR, Rodriguez-Lopes JN, Garcia-Canovas F: Effect of L-ascorbic acid on the monophelase activity of tyrosinase. Biochem J 1993;295:309–312.
3.
Nomura H, Ishiguro T, Morimoto S: Studies on L-ascorbic acid derivatives. II. L- Ascorbic acid and 3-phosphate and 3-pyrophosphate. Chem Pharm Bull (Tokyo) 1989;17:381–386.
4.
Kameyama K, Sakai C, Kondoh S, Yonemoto K, Nishiyama S, Tagawa M, Murata T, Ohnuma T, Quigley J, Dorsky A, Bucks D, Blanock K: Inhibitory effect of magnesium L-ascorbyl-2-phosphate (VC-PMG) on melanogenesis in vitro and in vivo. J Am Acad Dermatol 1996;34:29–33.
5.
Westerhof W: CIE Colorimetry; in Serup J, Jemec GBE (eds): Handbook of Noninvasive Methods and the Skin. Boca Raton, CRC Press, 1995, pp 385–397.
6.
Mosher DB, Fitzpatrick TB, Ortonne JP, Hori Y: Hypomelanoses and hypermelanoses; in Freedberg IM, Eisen AZ, Wolff K, Austen KF, Goldsmith LA, Katz SI, Fitzpatrick TB (eds): Dermatology in General Medicine, ed 5. New York, McGraw-Hill, 1999, pp 996–997.
7.
Jimbow K, Minamitsuji Y: Topical therapies for melasma and disorders of hyperpigmentation. Dermatol Ther 2001;14:35–45.
8.
Grimes PE: Melasma: Etiologic and therapeutic considerations. Arch Dermatol 1995;131:1453–1457.
9.
Piamphongsant T: Treatment of melasma: A review with personal experience. Int J Dermatol 1998;37:897–903.
10.
Lee SH, Choi EH, Feingold KR, Jiang S, Ahn SK: Iontophoresis itself on hairless mouse skin induces the loss of the epidermal calcium gradient without skin barrier impairment. J Invest Dermatol 1998;111:39–43.
11.
Green PG, Flanagan M, Shroot B, Guy RH: Iontophoretic drug delivery; in Walkers KA, Hadgraft J (eds): Pharmaceutical Skin Penetration Enhancement. New York, Dekker, 1993, pp 311–333.
12.
Chien YW, Siddiqui O, Shi WM, Lelawongs P, Liu JC: Direct current iontophoretic transdermal delivery of peptide and protein drugs. J Pharm Sci 1989;78:376–384.
13.
Grimmes S: Pathways of ionic flow through human skin in vivo. Acta Derm Venereol (Stockh) 1984;64:93–98.
14.
Suzuki H: Skin lightening with iontophoresis of L-ascorbic acid-2-phosphate (in Japanese). J Jpn Soc Aesthet Plast Surg 1998;20:46–67.
© 2003 S. Karger AG, Basel
2003
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.